Drug news

Campath/MabCampath (Sanofi/Genzyme) withdraws marketing in EU and US for oncology indications.

Read time: 1 mins

Last updated:21st Aug 2012

Published:21st Aug 2012

Source: Pharmawand

Sanofi/Genzyme have withdrawn MabCampath (alemtuzumab) from the European market and established a free distribution programme for B-cell CLL users. In the United States the FDA licence will be maintained but a free Campath Distribution Program will offer the drug freely to patients. The intention is to avoid confusion between Campath/MabCampath and the newly developed version of alemtuzumab for which Sanofi/Genzyme is seeking approval in the US and EU as Lemtrada for the treatment of Multiple Sclerosis and to avoid off-label prescribing of the oncologic version to Multiple Sclerosis patients when it is finally approved.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approves high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) injection, interchangeable biosimilar to Humira

Boehringer Ingelheim announced that the FDA has approved the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable* biosimilar to Humira (adalimumab), to treat multiple chronic inflammatory diseases

1 mins

Drug news

FDA approval for Inceptiv closed-loop spinal cord stimulator stimulator (SCS)for the treatment of chronic pain

Medtronic plc announced that the FDA has approved the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain

1 min

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 min

See all news